BioZorb Marker Lawsuit 2026: A Practical Guide to the Recalled Breast Tissue Marker Claims

If you had a lumpectomy and walked out with a BioZorb marker sitting under your incision, here’s the honest starting point: this isn’t a hypothetical future lawsuit anymore. My read is that the BioZorb litigation has already moved past the “should I file” stage for a large group of patients and into a messier, more interesting phase — figuring out who actually falls inside a settlement that was finalized in January 2026, and who’s still outside it with an open claim.

BioZorb is a small, implantable device designed to solve a real clinical problem. After breast-conserving surgery, the tissue around the tumor bed shifts as it heals, which makes it harder for a radiation oncologist to aim treatment precisely at the right spot months later. BioZorb was supposed to fix that by leaving a marker behind — one that would eventually dissolve on its own. The complaint at the center of this litigation is that, for a meaningful number of patients, it didn’t dissolve quietly. It moved. It pushed through the skin. It caused pain that lingered long after the cancer treatment itself was supposed to be over.

This article isn’t legal advice. It’s a plain-language walk-through of the recall, the litigation, and the settlement, built from FDA records and public court filings, meant to help you ask the right questions when you talk to an actual attorney.

---

What is BioZorb, and what actually went wrong with it?

BioZorb — and its smaller sibling, BioZorb LP — is built from two parts: a set of titanium clips that stay in the body permanently for imaging purposes, and a spiral bioabsorbable scaffold that’s supposed to break down over one to two years. Hologic manufactures it today, having acquired the device’s original developer, Focal Therapeutics, back in 2018.

On paper, the design is elegant. In practice, adverse event reports filed with the FDA tell a messier story. Instead of dissolving cleanly, the scaffold in some patients shifted position, sometimes migrating away from the original tumor bed. In more serious cases, the device pushed toward the skin over time and eventually eroded through it — a complication clinicians call extrusion. Add in infection, seroma, chronic pain, and a device that patients could simply feel under the skin, and you get a pattern of cases where the fix for cancer treatment planning became its own separate medical problem, often requiring an additional surgery just to take the marker back out.

For a patient who had already been through a cancer diagnosis and a lumpectomy, going back under the knife to remove a device that was supposed to help is exactly the kind of harm this litigation was built to address.

---

Why was BioZorb recalled, and how bad was it?

The FDA put out a safety communication in February 2024 flagging migration and erosion risk in BioZorb devices — a signal that regulators had already seen enough reports to warn clinicians directly. Hologic followed on October 24, 2024, with a voluntary recall of all unsold BioZorb and BioZorb LP lots. The FDA classified it as Class I, its most severe recall category, reserved for products where continued use could cause serious injury or death.

The numbers behind that recall matter. Since the device launched in 2015, roughly 91,531 units had been sold, and Hologic had logged 399 complaints, with 188 directly tied to adverse events by the time of the recall. That’s not a rounding error in a device this size — it’s a meaningful complication rate that regulators took seriously enough to act on.

Importantly, the recall applied to unsold inventory, not to devices already implanted. Patients weren’t told to rush in for removal. The clinical guidance was — and largely still is — that asymptomatic patients don’t need preventive removal, but should be monitored and should report new symptoms immediately.

Date	What happened
February 2024	FDA safety communication warns of migration and erosion risk
October 24, 2024	Hologic voluntarily recalls all unsold BioZorb/BioZorb LP lots
At recall	~91,531 units sold since 2015; 399 complaints, 188 tied to adverse events
Recall classification	FDA Class I (most serious)

---

Who actually qualifies to bring a claim?

Not every patient who received a BioZorb marker has a viable case. The dividing line is documented harm, not just the presence of the device.

Eligibility factor	What it typically requires
Confirmed implantation	Operative report or device ID card showing BioZorb/BioZorb LP was used
Documented complication	Medical records showing migration, erosion/extrusion, infection, seroma, or chronic pain
Additional treatment	Evidence of further treatment or a removal surgery tied to the complication
Provable damages	Medical bills, lost income, and documented pain and suffering
Timing	Claim filed within your state’s statute of limitations, generally counted from diagnosis or removal date

Simply feeling the device under your skin, without a documented complication requiring care, is a weaker starting point. On the other hand, if you already had a removal surgery with a pathology report and imaging on file, that’s exactly the kind of record an attorney needs to evaluate your case quickly.

---

How did the litigation get to where it is now?

Individual BioZorb lawsuits were filed across the country, but because they raised overlapping factual and legal issues, they were consolidated for pretrial proceedings in the U.S. District Court for the District of Massachusetts — not coincidentally, where Hologic is headquartered, in Marlborough. Using Federal Rule 42(a), Judge Allison D. Burroughs took on the job of managing the consolidated cases rather than each one proceeding on its own separate track.

Hologic pushed back hard along the way, filing multiple motions for summary judgment. The court denied several of them, and rulings split depending on how individual surgeons testified about causation in each case — a reminder that in device litigation, the operating surgeon’s deposition testimony often carries as much weight as the FDA paperwork. Four bellwether trials were actually scheduled between January and April 2026, which is a meaningful signal on its own: cases don’t get scheduled for real jury trials unless a court believes there’s substance behind the claims.

Before those bellwether trials could really get underway, the two sides reached an agreement in principle in November 2025. That agreement was formalized into a signed settlement on January 7, 2026, covering roughly 200 plaintiffs. The deal is fully funded by Hologic’s liability insurance, involves no admission of fault, and is contingent on a minimum participation threshold among eligible plaintiffs before the bulk of the covered cases are dismissed with prejudice.

---

What does compensation typically cover?

Mass tort settlements almost never pay a flat amount per plaintiff. Instead, a claims process typically weighs several categories of harm and allocates payouts based on severity and documentation. The categories that have come up repeatedly in BioZorb cases include:

Damages category	What it covers
Medical expenses	Diagnosis, treatment of infection, and removal surgery costs
Pain and suffering	Chronic pain and the physical/emotional toll of repeat surgery
Lost income	Wages lost during recovery from a removal procedure
Follow-up care	Wound care, scar revision, and additional imaging
Incidental costs	Caregiver help and travel to appointments

Here’s the part worth being blunt about: no public settlement matrix or total settlement fund figure has been disclosed, and no ethical attorney will hand you a specific dollar figure before reviewing your records. Be skeptical of any ad or intake call that promises a precise payout before your case has even been evaluated — actual allocations depend heavily on how documented and severe your complications were.

On taxes: under IRC Section 104, damages tied to physical injury are generally not taxable at the federal level, but punitive damages and non-physical emotional distress components can be. Talk to a CPA once you actually have a number, not before.

---

What’s the realistic timeline from here?

Stage	When	What it means
FDA safety communication	February 2024	First formal warning on migration/erosion risk
Class I recall	October 2024	Unsold inventory pulled from the market
Case consolidation	2024–2025	Lawsuits centralized before Judge Burroughs in Massachusetts
Summary judgment battles	2025	Several Hologic motions denied; bellwether trials scheduled
Agreement in principle	November 2025	Both sides agree to settle broadly
Signed settlement	January 7, 2026	~200 plaintiffs covered, contingent on participation threshold
Claims processing	Ongoing in 2026	Eligibility review, documentation, and payout allocation underway

A signed settlement is not the same thing as a check in the mail. Claims administration — verifying eligibility, reviewing medical records, and calculating individual payouts — routinely takes many months to a couple of years in mass torts of this size. Anyone telling you payments are imminent for every claimant is getting ahead of the actual process.

---

How should you actually pick a lawyer at this stage?

Choosing counsel now is a slightly different exercise than it would have been in 2024. You’re not just looking for someone willing to file a complaint — you need someone who understands exactly how the January 2026 settlement is structured and can tell you plainly whether your case fits inside it.

Questions worth asking directly:

• Have you actually handled BioZorb cases consolidated in the District of Massachusetts, or do you just run intake ads?
• Is this strictly contingency fee, with no upfront cost — and what’s the actual percentage, typically in the 33–40% range?
• Can you explain the settlement’s participation deadline and what happens if my case falls outside it?
• Will you take on a newer case, diagnosed after the settlement was negotiated, or are you telling me the door is closed?

Most firms offer free consultations, so it’s worth comparing two or three before committing, especially on how specifically they answer that last question.

---

What mistakes should you avoid?

Assuming the settlement means it’s too late. The January 2026 deal largely addresses cases filed by that point. Newer diagnoses or removal surgeries may still have an independent path forward.

Removing the device without a documented medical reason. If you push for removal absent a clinical indication, it can weaken the causation argument later. Get it in your surgeon’s notes first.

Letting the statute of limitations quietly expire. Deadlines vary by state and typically run from your diagnosis or removal date. “I’ll deal with it later” is the single most common way people lose a valid claim.

Posting details about your case on social media. Defense counsel routinely uses this kind of material to argue your injuries aren’t as serious as claimed.

Signing anything based on a promised dollar amount. No confirmed payout formula is public. Treat specific number promises with real skepticism.

---

What should you do right now?

1. Locate your operative report and device identification card.
2. Book an evaluation with a breast surgeon if you have any symptoms at all.
3. Collect every record tied to a complication, treatment, or removal surgery.
4. Get a free consultation with a product liability attorney experienced in device litigation.
5. Confirm the filing deadline that applies in your state.
6. Stay off social media about the case.

---

What should you do with a settlement once it lands?

It’s worth noticing that this entire settlement is being paid out of Hologic’s liability insurance, not company cash — a good reminder of how much manufacturer risk in cases like this actually sits with insurers rather than the company itself. If you’re thinking about where settlement funds eventually go once the tax and legal questions are settled, it’s reasonable to look at building a diversified base rather than parking everything in one place. Some readers rebuilding a portfolio after a payout look at steady, well-known names for a starting allocation — our Microsoft stock outlook 2026 is a common reference point for a large, diversified tech holding, while our Nike stock outlook 2026 and Dick’s Sporting Goods stock outlook 2026 cover two very different consumer-facing businesses worth comparing if you want exposure outside of tech.

None of that replaces the legal or tax work. Get your settlement documentation squared away with your attorney and CPA first, and treat any investment moves as a completely separate decision made on your own timeline.

If this is your first time dealing with a device-defect claim, it helps to see how similar cases have played out. Our guide to the hernia mesh lawsuit 2026 and the Exactech knee and hip recall litigation 2026 cover comparable device-defect fact patterns. If you want a clearer sense of how long payouts actually take after a settlement is signed, read our mass tort settlement payout timeline 2026, and if you’re still deciding whether to hire a lawyer at all, our breakdown of personal injury lawyer fees 2026 explains exactly how contingency arrangements work in practice.

---

Related reading

• Hernia mesh lawsuit 2026
• Exactech knee and hip recall lawsuit 2026
• Mass tort settlement payout timeline 2026
• Personal injury lawyer fees 2026

---

This article is for general informational purposes only and is not legal or medical advice. Whether you have a viable claim, what statute of limitations applies to you, and what compensation you might realistically expect all depend on your individual facts. Speak with a products liability attorney about your legal options and with a breast surgeon about your medical care. Outcomes are never guaranteed.